Lincoln Pharmaceuticals Limited
Valuation (93/100) does the heavy lifting; momentum (33/100) is the drag.
Buy zoneLincoln Pharmaceuticals Limited earns a Buy from StocksWizard, with a blended score of 62/100. At ₹577.15 it trades below our blended DCF and relative-multiples fair value of ₹1,154.3, about 100% upside to that estimate — we read it as undervalued by 100%. On 13.2x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 24% below its 52-week high of ₹758.15 and 30% above the low of ₹444.2. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. It clears 10 of 13 investability checks, with durability 62, valuation 86 and momentum 33 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹923.44. Low-confidence estimate — limited data.
1-year price
EOD · 2026-07-3152-week range
-23.87% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy62Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 12.3%
- Pass: Low debt (D/E < 0.5): 0.01x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 11%
- Pass: Earnings growing: 1%
- Pass: Net margin ≥ 10%: 13.1%
- Pass: Current ratio > 1.5: 5.25
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 7.24
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter56.1%
- Institutions1.1%
- Public & other42.8%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 7.24.
Opportunities
- Trading in our value buy zone versus sector peers.
- Trades ~100% below our estimated fair value.
About Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited manufactures and trades pharmaceutical products in India across multiple therapeutic categories including anticold, antibiotic, pain management, gastroenterology, anti-malarial, anti-fungal, corticosteroids, dermatology, anti-diabetic, anti-hypertensive, gynecology, cardiology, central nervous system, respiratory, and dyslipidemic treatments. The company offers branded generics and exports to approximately 60 countries including Europe and Canada.
Lincoln Pharmaceuticals Limited — frequently asked questions
Is Lincoln Pharmaceuticals Limited a buy, hold or sell?
StocksWizard currently rates Lincoln Pharmaceuticals Limited (LINCOLN) a Buy, based on a blended score of 62/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Lincoln Pharmaceuticals Limited's fair value?
Our blended DCF and relative-valuation model estimates Lincoln Pharmaceuticals Limited's fair value at about ₹1,154.3, versus a current price of ₹577.15 — roughly 100% upside. On that basis the stock looks undervalued by 100%.
Is Lincoln Pharmaceuticals Limited financially healthy?
Lincoln Pharmaceuticals Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Lincoln Pharmaceuticals Limited's share price performed?
Lincoln Pharmaceuticals Limited is down 15% over three months, and last traded at ₹577.15. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.